Imfinzi, a PD-L1 inhibitor medication, is used to treat multiple types of cancer by blocking the PD-L1 protein that allows cancer cells to evade the immune system. Administered every 2-3 weeks by a healthcare professional, clinical trials have shown Imfinzi to be an effective treatment that can lead to longer survival times for patients with advanced bladder and lung cancer. Although there are side-effects, including fatigue and gastrointestinal issues, discussions with a healthcare provider can help determine if Imfinzi is a viable and promising treatment option for patients with certain types of cancers.